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Leishmania (Viannia) panamensis (L. (V.) p.) is the main causative agent of cutaneous
leishmaniasis in Colombia and is usually treated with either meglumine antimoniate (MA)
or miltefosine (MIL). In recent years, there has been increasing evidence of the emergence
of drug-resistance against these compounds. Neutrophils are known to play an important
role in immunity against Leishmania. These cells are rapidly recruited upon infection and
are also present in chronic lesions. However, their involvement in the outcome of infection
with drug-resistant Leishmania has not been examined. In this study, human and murine
neutrophils were infected in vitrowith MA or MIL drug-resistant L. (V.) p. lines derived from
a parental L. (V.) p. drug-susceptible strain. Neutrophil effector functions were assessed
analyzing the production of reactive oxygen species (ROS), the formation of neutrophil
extracellular trap (NET) and the expression of cell surface activation markers. Parasite
killing by neutrophils was assessed using L. (V.) p. transfected with a luciferase reporter.
We show here that MA and MIL-resistant L. (V.) p. lines elicited significantly increased
NET formation and MA-resistant L. (V.) p. induced significantly increased ROS production
in both murine and human neutrophils, compared to infections with the parental MIL
and MA susceptible strain. Furthermore, neutrophils exposed to drug-resistant lines
showed increased activation, as revealed by decreased expression of CD62L and
increased expression of CD66b in human neutrophils yet presented higher survival
within neutrophils than the drug-susceptible strain. These results provide evidence that
parasite drug-susceptibility may influences neutrophil activation and function as well as
parasite survival within neutrophils. Further investigaton of the inter-relationship of drug
susceptibility and neutrophil effector function should contribute to better understanding
of the factors involved in susceptibility to anti-Leishmania drugs.
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INTRODUCTION
Cutaneous leishmaniasis is an important public health problem
affecting 98 countries and territories worldwide. Approximately
350 million people live in endemic areas and over 2 million
new cases are reported annually (1). In Colombia, L. (V.) p.
is responsible for the majority of reported cases of cutaneous
leishmaniasis (2) though L. (V) braziliensismay be more frequent
among occupationally exposed military personnel (3). The first
line of treatment in Latin America (4) and most of the world,
consists of parenteral administration of meglumine antimoniate
(MA) (5). Oral miltefosine (MIL) is generally administered as
the second line treatment. In recent years, there has been an
increasing number of reports of treatment failure and loss of
susceptibility of clinical Leishmania strains to antimonial drugs,
and association of resistance in some cases of therapeutic failure
in leishmaniasis patients. The reported frequency ofMA andMIL
tolerance ranges from 10 to 70% and varies among Leishmania
species and by geographic origin. The underlying mechanisms
contributing to anti-leishmanial treatment failure in Colombia
and the rest of the world are poorly understood (6–8).
It is well established that the outcome of anti-leishmanial
treatment is not solely dependent on parasite drug-susceptibility,
but also on intrinsic host factors. The interplay between parasites,
the host and the immune response is also a factor determining the
clinical outcome of Leishmania infection and treatment (9, 10).
There is currently a lack of information on the role of neutrophils
in Leishmania infection and its impact on drug-susceptibility.
Recently, high levels of transcriptional signatures associated with
chemokines promoting neutrophil recruitment were observed in
L. (V.) p. infected primarymacrophages and in chronic cutaneous
lesions of CL patients, suggesting a potential role for neutrophils
in the chronicity of infection (11).
Neutrophils are essential phagocytes of the innate immune
system and the most abundant leukocytes in human circulation
(12). They usually are the first cells recruited to the site of
infection upon pathogen entry into a host (13). Neutrophils
possess three major effector killing strategies: phagocytosis and
subsequent production of reactive oxygen species (ROS), the
release of granules that contain microbicidal proteins (14) and
the formation of neutrophil extracellular traps (NETs). NETs are
fibrous structures composed of dsDNA coated with a variety
of different microbicidial proteins that can trap and kill a
variety of pathogens (15). Upon phagocytosis of pathogens,
neutrophils produce different reactive oxygen species that are
synthesized by the enzymatic activity of NADPH-synthase (16).
Indeed, a lack of NADPH-function manifests itself in higher
susceptibility to a variety of infections and is known as chronic
granulomatous disease (17). Also a lack of Myeloperoxidase
(MPO), an enzyme that catalyzes the synthesis of highly
microbicidal hypochlorous acid, is thought to lead to increased
susceptibility to infection (18). Neutrophil granules can either
fuse with pathogen containing phagosomes or be released into
the extracellular space (19).
Increasing evidence points toward a crucial role of neutrophils
in leishmaniasis (20, 21). It has been shown that neutrophils
are massively recruited to the site of infection upon infection
with L. major (22–25), L. amazonensis (26), L. brazilensis (27),
L. mexicana (28), L. infantum (29), and L. donovani (30, 31) and
that a subset of L. mexicana can even use these cells to replicate
(32). While neutrophils are well known to have a protective role
in many infections they can have either beneficial or detrimental
roles in leishmaniasis depending on the Leishmania spp. involved
(21). In most studies performed in murine models, the lack
of neutrophils was beneficial to disease outcome in Leishmania
infection. Furthermore, parasites are known to use these cells as
“Trojan horses” to enter silently into the host macrophages (33).
In contrast, neutrophil presence has been reported to positively
affect disease outcome in the case of L. braziliensis (25, 34–36), L.
amazonensis (37) and L. donovani infection (38).
Here, using both human and mouse neutrophils, we have
investigated in vitro the role of these cells in the context of
anti-Leishmania drug resistance following L. (V.) p infection,
focusing on whether drug resistance could be linked to elicitation
of distinct neutrophil activation profiles.
We found that L. (V.) p. lines with divergent drug-
susceptibility to miltefosine and meglumine antimoniate have
different effects on neutrophil phenotype and functionality. Our
data show that neutrophils are differentially activated by drug-
resistant and drug-susceptible parasites and that drug-resistant
parasites are less affected by neutrophil microbial function than
drug-susceptible parasites. These differences in the elicitation
of neutrophil function and parasite killing may influence anti-
leishmanial drug therapy.
MATERIALS AND METHODS
Mice
C57BL/6 mice (5–10 weeks old) were purchased from Envigo
(Cambridgeshire, United Kingdom) and bred under specified
pathogen-free conditions at the animal facility of the University
of Lausanne in Epalinges.
Ethics Statement
All procedures involving human blood samples were approved
by the Ethical Committee of the Canton of Vaud (CER-VD
2017-00182). Written informed consent was obtained from the
healthy blood donors participating in this study. The study was
conducted in compliance with the legislation of the Canton of
Vaud and the Swiss Confederation as well as the declaration
of Helsinki. Animal experimentation protocols were approved
by the veterinary office of the Canton of Vaud (Authorization
1266.6-7 to F.T-C.) and were done in accordance to cantonal
and federal law as well as the principles of the declaration of
Basel. This study and the use of patient derived Leishmania
strains and lines derived from these strains were approved by
the Ethics Committees of CIDEIM- Colombia, in accordance
with the national and international guidelines for Good Clinical
Practice.
Leishmania (Viannia) Panamensis
Parasites
The L. (V.) p. strain (MHOM/COL/86/1166LUC) WT-control
was used to derive the strains resistant to potassium antimony
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(III) tartrate hydrate (39) and miltefosine as described previously
(40). Briefly, L. (V.) p. promastigotes were cultured in media
containing increasing concentrations of drugs, either up to
2885µM Sb or up to 60µM of miltefosine. Upon establishment
of drug-resistance, the strains were cultured in RPMI (Gibco)
with 10% FCS and 1% PNS at 26◦C. Antimony resistant
parasites (MHOM/COL/86/ LUC 1166-1000.1) were cultured
in medium containing 1 mM/L SbV. The miltefosine resistant
parasites (MHOM/COL/86/1166-LUC056) were cultured in
medium containing 60 µM/L miltefosine. Luciferase expressing
strains were grown in medium containing 60µMG418 (Sigma).
Snarf-1 Staining of Leishmania (Viannia)
Panamensis Parasites
Parasites were stained with the intracellular dye SNARF-
1 (Thermofisher) to render them fluorescent. Parasites were
incubated in 6µM solution of SNARF-1 in PBS for 30min
and subsequently washed twice. SNARF-1 stained fluorescent
parasites were detected at an excitation wavelength of 488 nm and
an emission wavelength of 610 nm.
Drug-Susceptibility Screening
Drug-susceptibility of parasites was measured as a reduction
of intracellular L. (V.) p. amastigote burden in macrophages
derived from a U-937 cell line as described previously (40).
Briefly, 1.2 × 105 U-937 cells were treated with phorbol 12-
myristate 13-acetate (PMA; 100 ng/ml; Sigma) to differentiate
them into macrophages. Cells were co-cultured with L. (V.)
p. promastigotes opsonized with 10% AB positive human
serum at a MOI of 5:1 and incubated for 24 h at 34◦C.
Subsequently, the culture medium was replaced with RPMI
containing either 16µM miltefosine or 32µg/ml Sb(V) and the
cells were incubated for another 48 h. The Sb-containingmedium
was replaced after 24 h whereas the miltefosine-containing
medium was not replaced during the 48 h of incubation. Parasite
burden was assessed by light microscopy in four replicates by
2 microscopists in a blinded manner. The cut-offs defining
sensitive respectively resistant strains were based on a previously
published analysis (40). A dose response survival curve was
done to establish the half maximal response of the drugs on
intracellular amastigote macrophage killing (EC50), as previoulsy
described (8). Briefly, the EC50 in presence of miltefosine for
the WT L. (V.) p. strain was 2.1 µM/liter and the macrophage
infection was 67% for the L. (V.) p MIL-R stain; the EC50 was
>32 µM/liter with 70% of macrophage infection. In presence
of Sb(V), the EC50 for the WT L. (V.) p. was 10 µM/liter with
73% macrophage infection, and for the L. (V.) p. MA-R strain
the EC50 was >128 µM/liter with macrophage infection of 69%
(mean of three independent experiments).
Isolation Metacyclic Leishmania (Viannia)
Panamensis Parasites
Metacyclic L. (V.) p. parasites were isolated using a Percoll
(GE Healthcare) density gradient. Parasites were resuspended in
45% Percoll-medium suspension and layered onto 60% and 90%
Percoll-medium suspension phases. After centrifugation without
brakes at 4300 g for 45 min, metacyclic parasites were isolated
from the 45%/60% Percoll-medium suspension interphase (41).
The parasites were washed twice and counted using a Neubauer
chamber.
Human Neutrophil Isolation
Peripheral blood neutrophils were isolated from venous blood
of healthy volunteers. Density gradient centrifugation using
polymorphprep (Progen) was performed and the enriched
neutrophils were isolated according to the manufacturer’s
instructions. The remaining red blood cells were lysed using
ACK-Buffer. Neutrophil purity was assessed using Cyto-Spin and
Quick-Fix staining and was established to be ≥95%. Twenty-
four hours post culture, 70% of neutrophils were viable (DAPI-).
Infection with parasites, independently of the susceptibility of the
parasites diminished neutrophil viability to 50–60%.
Murine Neutrophil Isolation
Bone marrow of the femora and tibia of C57BL/6 mice were
flushed with RPMI. Erythrocytes were lysed with ACK buffer,
the remaining leukocytes were washed and the neutrophils were
then isolated by negativeMACS using the neutrophil isolation kit
(Miltenyi Biotec) according to the manufacturer’s indications. At
24 h of culture, 90% of neutrophils were viable (DAPI−).
Assessment of Net Formation
3 × 105 Neutrophils were seeded on poly-L-Lysine coated
coverslips, primed with 25 ng/mL GM-CSF and exposed for
4 h with either L. (V.) p., PMA (Phorbol-12-myristate-13-
acetate, Sigma), PMA + DNase (Sigma) or without a stimulus.
Subsequently, cells were fixed with 4% PFA (Paraformaldehyde,
Sigma) and stained with rabbit anti-human MPO (Dako)
primary antibody andAlexa Fluor-488 goat anti-rabbit secondary
antibody (Life Technologies). Coverslips were mounted on glass
slides using a DAPI containing mounting medium (Molecular
Probes) and analyzed by confocal microscopy (ZEISS LSM
510). To quantify NET formation, NETs were counted using
fluorescence microscopy in a blinded manner based on at least
in three replicates. NET formation was also assessed through the
measurement of dsDNA in the supernatant using the Quant-
iT PicoGreen kit (Thermo Fisher) by adapting a technique
previously described (42). 2 × 106 neutrophils were incubated
for 4 h in X-vivo medium (Lonza) with either L. (V.) p., PMA
or PMA + DNase or without stimulus. After incubation, the
cell suspensions were centrifuged, and the supernatants were
collected and transferred into black 96-well plates (Perkin Elmer).
The picogreen dye was added and fluorescence was measured in
using a plate reader (Molecular Devices, SpectraMax MiniMax
300) at an excitation wavelength of 480 nm and an emission
wavelength of 520 nm.
Measurement of Reactive Oxygen Species
Production
ROS production was measured using a luminol-based
chemiluminescence assay. 5 × 105 neutrophils were incubated
with either L. (V.) p., PMA or without stimulus in white,
opaque 96-well plates (Perkin Elmer). Luminol (Carbosynth)
was added at a final concentration of 20µg/mL. ROS induced
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chemiluminescence was measured at all wavelengths with a plate
reader at 5 min intervals during 1 h.
Parasite Viability Measurement With
Luciferase Assay
5 × 105 neutrophils were infected with luciferase-expressing
L. (V.) p. strains with different drug-susceptibility phenotypes
during 2 h at 34◦C at a MOI of 5:1, washed and subsequently
incubated for 24 h. Parasite viability after incubation was
measured using a luciferase assay system (Promega) according
to the manufacturer’s instructions. To measure parasite
viability in presence or absence of NETs, neutrophils were
incubated with or without 10µg/ml DNase and parasite survival
measured by chemi-luminescence as previously described (28).
Chemiluminescence was measured in white, opaque 96-well
plates in a plate reader (Molecular Devices, SpectraMaxMiniMax
300) at all wavelengths.
Identification of Neutrophil Cell Surface
Markers and Measurement of Cell Viability
by Flow Cytometry
Surface activation markers and cell viability markers in
blood derived human neutrophils were analyzed using
Flow Cytometry analyzer of either the BD LSR II or the
BD LSR Fortessa series (Becton Dickinson) and analyzed
with FlowJo software (Tree Star). The following antibodies
were used: Anti-human: CD15-APC, CD62L-PerCP-
efluor710, CD66b-PE-Cy7. Anti-mouse: Ly6G(1A8)-APC-Cy7,
CD62L-PE, CD11b-PE-Cy7 (all from e-Bioscience). Cell
viability: Live/Dead fixable Aqua Dead Cell Stain Kit
(Invitrogen).
RESULTS
Increased Reactive Oxygen Species
Production by Murine and Human
Neutrophils Challenged With
Miltefosine-Resistant Leishmania (Viannia)
Panamensis Strains
To investigate the contribution of neutrophils in the intracellular
survival of Leishmania during drug exposure, we first
investigated whether L. (V.) p. strains susceptible or resistant to
MA or MIL would induce different phenotype and function in
neutrophils. The production of ROS by neutrophils is known
to be an important defense mechanism against pathogens (43)
and also contributes to NET formation (44). Therefore, we
analyzed ROS production during the first hour of incubation of
neutrophils with the different L. (V.) p. populations. Parasites
that are resistant to miltefosine induced 1.5 times more ROS
production compared to drug-susceptible parasites in BM-
derived murine neutrophils (Figures 1A,B) and more than
two times as much ROS production than drug-susceptible
parasites in blood-derived human neutrophils from healthy
donors (Figures 1C,D). In contrast, the induction of ROS
by antimony resistant parasites strains in neutrophils did
not differ from drug-susceptible L. (V.) p. parasites. Even
though all L. (V.) p. strains induced ROS in neutrophils,
these results show that the drug-susceptibility phenotype,
specifically MIL-resistance, influences neutrophil ROS
production.
Drug-Resistant Leishmania (Viannia)
Panamensis Induce More Neutrophil
Extracellular Trap Formation Than
Drug-Susceptible Strains in Murine and
Human Neutrophils
Next, to visualize NETs, neutrophils were infected with L. (V.)
p. of different drug susceptibility and NET formation analyzed
by confocal microscopy. NETs were stained with DAPI to
detect DNA filaments and an MPO mAb to detect the MPO
associated with it. All parasite populations tested induced NET
formation in both murine and human neutrophils as observed by
DNA-MPO co-localization (Figure 2A). Drug resistant parasites
induced substantially more NETs (two to three times) in
murine and human neutrophils compared to drug-susceptible
parasites (Figures 2B,C). We observed parasites in association
with the NETs, a process more easily detectable in human
NETs. To confirm these results, we used the picogreen assay
that measures the amount of dsDNA released by neutrophils
into the supernatant (42). We again observed that drug-resistant
L. (V.) p. parasites induced a significantly higher amount
of dsDNA release compared to drug-susceptible parasites in
human and murine neutrophils (Figure 3). Collectively, these
results demonstrate that MIL and MA-resistant L. (V.) p lines
induce more NET formation than the parental drug-susceptible
strain.
Modulation of Neutrophil Activation
Markers by Leishmania (Viannia)
Panamensis of Different
Drug-Susceptibility Phenotypes
We next investigated if exposure of neutrophils to L. (V.) p. of
different drug-susceptibility would result in distinct modulations
of cell surface markers. Using flow cytometry, we observed
that BM-derived murine neutrophils exposed to MIL and MA
drug-resistant L. (V.) p lines expressed more CD11b (Mac-
1) and CD62L (L-selectin) on their surface than neutrophils
exposed to drug-susceptible L. (V.) p. (Figure 4). CD62L and
CD66b (exocytosis of secondary granules) expression by human
neutrophils derived from the blood of healthy individuals
exposed to drug-susceptible and resistant L. (V.) p was analyzed
by flow cytometry (Figures 5A–C). MA and MIL resistant
parasites elicited a decrease in expression of CD62L and
an increase in expression of CD66b (Figures 5D–E). These
data show that both human and murine neutrophils exposed
to drug-resistant L. (V.) p. lines are activated to a greater
extent and have a phenotype that is more associated with
extravasation, compared to neutrophils challenged with drug-
susceptible L. (V.) p.
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FIGURE 1 | Miltefosine (MIL)-resistant L. (V.) p. parasites induce more ROS production in murine and human neutrophils than the meglumine antimony (MA)-resistant
or drug susceptible strains. ROS production was measured using a luminol based chemiluminescence assay. Bone marrow derived murine neutrophils and
blood-derived human neutrophils from healthy donors were incubated with either MIL-, MA-resistant or susceptible L. (V.) p., PMA or without stimulus. Luminol was
added and ROS-induced chemiluminescence was measured with a plate reader every 5min during 1 h. (A,C) One representative curve of ROS-induced luminol
chemiluminescence values in murine (A) and human (C) neutrophils. (B,D) The corresponding area under the curve (AUC) at 60min of measurement for murine
(B) and human (D) neutrophils. *p < 0.05, *a MIL-R compared to WT, *b MIL-R compared to MA-R, WT, wild type; MA-R, Resistant to meglumine antimoniate; MIL-R,
Resistant to miltefosine; the data are pooled from three (human) or two (mouse) independent experiments.
FIGURE 2 | Murine and human neutrophils form more NETs when exposed to L. (V) p. strains that are resistant to either meglumine antimonate or miltefosine.
Neutrophils were seeded on poly-L-Lysine coated coverslips and exposed for 4 h with either L. (V.) p.of the indicated drug suceptibility, PMA, PMA + DNase or
without stimulus. Subsequently, cells were fixed, stained with anti-human MPO and DAPI (A) Confocal microscopy images of neutrophils upon exposure to L. (V.) p.
murine or human neutrophils exposed to strains of SNARF-1 labeled L. (V.) p. promastigotes lines that were either resistant or susceptible to meglumine antimonate
(MA) or miltefosine (MIL) at a 5:1 parasite-cell MOI. (B,C) The frequency of murine (B) or human (C) neutrophils forming NETs was counted with a fluorescence
microscope. *p < 0.05, each point corresponds to one healthy blood donor or one mouse. One representative experiment out of four is shown. The arrows point to
colocalization of parasites with NETs. Zoom in of NETs are shown for murine neutrophils -The scale bar corresponds to 50µM.
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FIGURE 3 | Murine and human neutrophils release more dsDNA when exposed to L. (V) p. strains that are resistant to either MA or MIL. Bone marrow derived murine
neutrophils (A) and blood-derived human neutrophils from healthy donors (B) were exposed to L. (V.) p. of the indicated susceptibility at a 5:1 MOI. As controls,
incubations with PMA, PMA + DNase or without stimulus were also performed. Four hours later, NET formation was quantified by measuring the levels of double
stranded DNA (dsDNA) released in the supernatant using the PicoGreen fluorescent dye assay. *p < 0.05, *a MA-R or MIL-R compared to WT, *b MIL-R compared to
MA-R, Each point corresponds to one healthy blood donor or one mouse. One representative experiment out of four (human) and three (mice)independent
experiments is shown.
FIGURE 4 | Expression of cell surface activation markers of murine neutrophils in response to exposure to L. (V.) p. promastigotes with different drug-susceptibility
phenotypes. Bone marrow derived murine neutrophils were exposed to the indicated L. (V.) p. lines at a MOI of 1:10 or without stimulus for 90min. Incubation with
PMA was used as a positive control. Neutrophils were then stained with the CD11b and CD62L mAbs and surface expression was analyzed by flow cytometry.
(A) Representative flow cytometry plot indicating CD11b and CD62L positive and negative populations. (B,C) A representative histogram plot of normalized
fluorescence values of murine neutrophils stained with antibodies against CD11b and CD62L is shown. Normalized fluorescence values of murine neutrophils stained
with antibodies against CD11b and CD62L is shown. (C,D) MFI values of murine neutrophils stained with antibodies against CD62L and CD11b. WT, Wild type;
MA-R, Resistant to meglumine antimoniate; MIL-R, Resistant to miltefosine. The data is representative of three experiments. *p < 0.05.
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FIGURE 5 | Expression of surface activation markers of human neutrophils in response to exposure to L. (V.) p. metacyclic promastigotes of different
drug-susceptibility phenotypes. Blood-derived neutrophils from healthy donors were exposed to the indicated L. (V.) p. lines at a MOI of 1:10 or without stimulus for
90min. Incubation with PMA was used as a positive control. Neutrophils were then stained with the CD62L and CD66b mAbs and surface expression was analyzed
by flow cytometry. (A) Representative flow cytometry plot indicating CD62L and CD66b positive and negative populations. (B,C) One representative flow cytometry
plot of normalized fluorescence values of human neutrophils stained with antibodies against CD62L and CD66b that were exposed to different L. (V.) p. strains at a
MOI of 10. Is shown (D,E) MFI values of human neutrophils stained with antibodies against CD62L and CD11b. WT, Wild type; MA-R, Resistant to meglumine
antimoniate; MIL-R, Resistant to miltefosine. The data is representative of a total of five experiments. *p < 0.05.
Drug-Resistant Leishmania (Viannia)
Panamensis Strains Are More Resistant to
Neutrophil Parasite Killing 24h After
Infection
As we observed differences in ROS production, NET formation
and neutrophil activation in neutrophils exposed to L. (V.) p.
of different drug-susceptibility phenotypes, we assessed whether
this would have an impact on parasite killing. Luciferase
expressing L. (V.) p. lines of the indicated drug-susceptibility
phenotypes were exposed to murine or human neutrophils
for 24 h and parasite viability was analyzed by measuring
luciferase activity. Drug-resistant parasites were significantly
more resistant to neutrophil killing by murine and human
neutrophils than the drug-susceptible strain (Figures 6A,B). The
frequency of neutrophil infection observed 4 h after infection
with MA-R and MIL-R L. (V.) was significantly higher for
drug-resistant parasites than WT parasites (Figure 6C) and this
difference persisted 24 h post infection, suggesting diminished
susceptibility to neutrophil killing. To evaluate the possible
impact of NETs on parasite killing, luciferase-expressing WT,
MIL-R and MA-R L. (V.) p parasites were exposed to netting
neutrophils in presence or absence of DNAse. Four hours
later, the frequency of viable luciferase expressing parasites
was determined as previously described (28). The presence of
DNAse did not change the relative number of WT parasites,
suggesting no impact of NETs on parasite viability. In contrast,
treatment of NETs with DNAse significantly increased the
number of MA-R and even more so that of MIL-R L.(V.) p
parasites, suggesting partial killing of the parasites by NETs
(Figure 6D). Taken together, our data demonstrate that in both
murine and human neutrophils, drug-resistant L. (V.) p. lines
induce more mechanisms known to kill pathogens than the
drug-susceptible parasites, yet they are better able to resist
neutrophil killing even though partial killing by NETs was
observed.
DISCUSSION
Anti-leishmanial drug-resistance is an increasing concern in
Colombia, but also worldwide (45–47). In India miltefosine has
replaced antimony as the first line of treatment against visceral
leishmaniasis due to widespread evidence of antimony-resistance
(48). However, the efficacy of miltefosine has also dropped
considerably during the first 10 years following its introduction
(49–51). It is crucial to consider that parasite drug-resistance
is not equal to clinical treatment failure. Therapeutic response
is also determined by host factors, such as previous infection,
co-morbidities, nutritional status, pharmacokinetics etc. (52).
Nevertheless, drug-resistance is a very important determinant
of treatment failure, thus understanding how drug-resistance
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FIGURE 6 | Killing of L. (V.) p. of different drug susceptibilities by murine and human neutrophils. Neutrophils were infected with luciferase expressing L. (V.) p. lines
with different drug-susceptibility phenotypes for 2 h at 34◦C, washed and further incubated for 24 h prior to analysis. Parasite viability after incubation was measured
using a luciferase assay system. Murine (A) and human (B) neutrophils were exposed to luciferase expressing L. (V.) p. of the indicated drug susceptibility at a 5:1
MOI. 24 h later chemiluminescence was measured represented as relative light units and parasite killing was assessed MIL-R: Resistant to miltefosine, MA-R:
Resistant to meglumine antimoniate, freeze-thaw parasites were killed by 10 times of subsequent freezing and thawing, PMN: Neutrophils. One representative
experiment is shown out of four. (C) Infection frequency of neutrophils 4 h after exposure to the parasites of the indicated drug susceptibility. (D) Assessment of
parasite killing by NETs. Human neutrophils were exposed to parasites of the indicated susceptibility as in (B), but in addition, DNAse was added to the neutrophils as
indicated. This are representative experiments of two.
phenotype of L. (V.) p. impacts the anti-leishmanial immune
response is relevant to the understanding of the potential role of
neutrophils in therapeutic outcome.
Here, we have demonstrated for the first time that L.
(V.) p. parasites having different drug-susceptibility phenotypes
elicit distinct neutrophil effector functions, shown by a higher
induction of ROS production, NET formation and the expression
of surface markers characteristic of neutrophil activation. ROS
production is a crucial microbicidal mechanism of neutrophils,
but the impact of ROS on Leishmania survival is species and
host dependent (53). Here, we showed that L. (V.) p. induces
ROS production in murine and human neutrophils and that ROS
production is increased whenmurine and human neutrophils are
infected with the miltefosine-resistant L (V.) p. compared to the
drug-susceptible parasites. In contrast, exposure of neutrophils
to MA-R L. (V.) p. parasites had no significant impact on ROS
production, suggesting that increased ROS production is not a
general feature of parasites resistant to different drugs.
It has been reported that ROS production is critical for the
induction of ROS-dependent NET formation (54). Activation
and nuclear translocation of neutrophil elastase are crucial in
ROS-dependent NET formation, reviewed in Papayannopoulos
(55) and Brinkmann (56). However, there is also an NOX-
independent pathway of NET formation that does not depend
on ROS (57). L. amazonensis has been reported to induce
ROS-independent and ROS-dependent NET formation. In our
study, we show that MA-resistant and MIL-resistant L. (V.)
p. induce increased in NET formation compared to that of
susceptible strains, however only MIL-resistant L. (V.) p. induced
an increased ROS production compared to that obtained from
Frontiers in Immunology | www.frontiersin.org 8 December 2018 | Volume 9 | Article 3040
Regli et al. Parasite Drug-Resistance and Neutrophil Function
the drug-susceptible strain. These data suggests that the NET
formation induced by MA-resistant L. (V.) p. may be partly
ROS-independent.
The distinct activation profiles elicited by parasites having
a different drug resistance phenotype are consistent with the
absence of cross resistance i.e., Sb resistant parasites are not also
resistant to miltefosine and vice-versa nor is there implication
of a generic multi drug resistance mechanism. Resistance to
different drugs is likely the outcome of the convergence of host
cell and parasite responses to infection, their response to the
drug, and drug effects on the host response. Our data implicate
an association between the characteristics of the resistant
and susceptible parasite population and neutrophil response.
These characteristics could segregate with the susceptibility
phenotype without being directly and causally involved in drug
susceptibility. The neutrophil response elicited could enable the
microbicidal effect of the drug, or drug resistance could provide a
protective effect to neutrophil defense mechanisms as described
for Sb resistance and lower nitric oxide susceptibility reported for
some Leishmania spp. (58, 59).
Neutrophil effector functions contribute to microbial
destruction in most infections, however, their role in
leishmaniasis varies, depending on host factors and the
Leishmania spp. involved (21, 53). We observed L. (V.) p.
parasites associated with the filamentous structures of NETs,
which substantiates parasite trapping by these structures. Most
Leishmania spp. are trapped by NETs. Some, such as L. mexicana
(28), L. donovani (60) or L. infantum (61) survive NET exposure,
while others such as L. amazonensis (61–63) are killed by NETs,
at least in their promastigote stage. The higher survival of
drug-resistant parasites despite induction of greater ROS and
NET response suggests that these L. (V.) p. lines resist better to
neutrophil killing than L. (V.) p. susceptible strains. This is in
line with studies performed on macrophages, reporting that MA
as well as MIL-resistant Leishmania donovani strains were more
resistant to ROS mediated killing due to increased intracellular
thiol-levels (64–68). Neutrophil recruitment and increased
neutrophil activation are known to play a key role in many
inflammatory diseases (69, 70). Our results demonstrate that
there is an increase in neutrophil activation upon stimulation by
drug-resistant L. (V.) p. compared to drug-susceptible parasites.
It is therefore conceivable that treatment failure may result at
least in part due to the increased resistance of L. (V.) p. strains
to neutrophil effector functions. An increase in parasite survival
would then lead to an increase of inflammation and in turn
would lead to more neutrophil recruitment and activation, and
potentially constitute a self-sustaining circle.
In this study, we used laboratory-derived L. (V.) p. drug-
resistant lines. Since there are differences in the drug-resistance
mechanisms of parasites that develop drug-resistance in vivo
compared to those experimentally selected for drug-resistance
in vitro (7, 71) the assessment of the interaction of neutrophils
and L. (V.) p. with different drug-susceptibility phenotypes
that have been isolated from patients in a clinical setting
should further elucidate of the role of the interaction of L.
(V.) p. and neutrophils in anti-leishmanial responses. Also, the
study of the in vivo immune response of neutrophils against
those parasites would contribute to better understanding of the
role the immune system plays in anti-leishmanial treatment
outcome.
The concurrence of the present findings in mouse and
human neutrophils strengthens the observations and provides a
surrogate model to identify the mechanisms involved, in follow-
up investigations based on these findings. Further understanding
of the effect of drug-resistant parasites on neutrophil function,
including the analysis ROS production and NET formation ex
vivo (e.g., neutrophils from lesion biopsies or patient blood
samples), should be further investigated to assess ehether this
neutrophil activation could constitute a surrogate marker for
treatment outcome.
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